Author: Editor

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group gives an overview of his presentation, which focused on the use of IBM Watson technology for clinical trial matching at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6501: Cognitive technology addressing optimal cancer clinical trial matching and protocol feasibility in a community cancer practice

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses common questions colleagues ask him regarding the IBM Watson platform at the 2017 ASCO Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses the impact of IBM Watson on clinical practice and future research at the 2017 ASCO Annual Meeting in Chicago, IL.

Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL. Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC) and advanced melanoma: Phase 1 KEYNOTE-029 study

Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his second presentation, which focused on the use of nivolumab plus an anti-LAG 3 antibody for the treatment of metastatic melanoma at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9520: Initial efficacy of anti-lymphocyte activation gene-3 (antiLAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiPD-1/PD-L1 therapy

Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses what the next steps are for these two clinical trials and the impact of these studies on future clinical practice and research in metastatic melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Rini, MD of Cleveland Clinic gives an overview of the poster presentations on kidney cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Rini, MD of Cleveland Clinic gives an overview of his poster presentation which focuses on the use of sunitinib in advanced/metastatic renal cell carcinoma at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4597: Phase 3 KEYNOTE-426 trial: pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naïve advanced/metastatic renal cell carcinoma (mRCC)

Brian Rini, MD of Cleveland Clinic discusses the treatment trends for kidney cancer in the next couple of years which include combination therapy at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia discusses the take-home message of the AIM2CERV trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia discusses how he communicates and encourages his patients to participate in clinical trials, specifically the AIM2CERV trial. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia gives an overview of poster presentations he found the most interesting and exciting at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia discusses the unmet need for cervical cancer and the promising data coming out of the AIM2CERV trial, especially for patients with high risk of recurring disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of the treatment trends for 2017 in breast cancer treatment. He discusses two promising clinical trials on breast cancer that were presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses the next step for RAD1901 and his plans for the next trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of his presentation, Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses common questions he’s asked regarding his study on the use of elacestrant (RAD1901) for ER+ advanced breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer

Adi Diab, MD of MD Anderson Cancer Center discusses the treatment trends for 2017 in oncology, which include combining immunotherapies with chemotherapy at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center gives an overview of the promising data on intratumoral therapy that was presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center discusses the impact of cytokine therapy and NKTR-214 on clinical practice and future clinical trials, specifically its role in combination with other treatments at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center discusses a common question he’s asked, regarding the use of NKTR-214 for not only renal cell carcinoma and melanoma, but for other cancers as well. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center gives an overview of his abstracts, which focus on the use of NKTR-214 for treatment of patients with renal cell carcinoma and melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract e14040: A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors Abstract 2545: Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses whether or not there is a phase 3 trial in the works for the use of gilteritinib for treatment of relapsed/refractory acute myeloid leukemia. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology the future of treatment for metastatic urothelial cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses a phase 1 study of enfortumab vedotin for metastatic urothelial cancer, which was presented by Daniel Peter Petrylak, MD of Yale Cancer Center at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 106: A phase 1 study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of the results of the FAST Phase 2 Trial, which was presented by Martin H. Schuler, MD at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4028: Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction (GEJ), and esophageal cancers: Results from the FAST Study

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses the use of enzalutamide for men with metastatic castration-resistant prostate cancer. This abstract was presented by Gerhardt Attard, MD, PhD of The Institute of Cancer Research at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 5004: A Phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of an abstract presented by Jessica K. Altman, MD of Feinberg School of Medicine at Northwestern University, which focuses on gilteritinib for FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance gives an overview and background context on her abstract which focuses on t-cell therapy merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 3044: Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance discusses what’s next in the future for her clinical trial on t-cell therapy and avelumab for merkel cell carcinoma at the 2017 ASCO Annual Meeting in Chicago, IL.

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance explains what epitopes are in merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance gives an overview of her poster presentation which focuses on two trials of cellular immunotherapy for merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance discusses the promising data coming out of SCCA for acute lymphoblastic leukemia (ALL) and lymphoma at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance stresses the importance of patient advocacy, quality of life, and cancer care for patients and survivors at Seattle Cancer Care Alliance. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance gives an overview of a joint session between American Association of Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) on two types of liquid biopsies, circulating tumor cells and circulating tumor DNA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance discusses plans the center has on the future of cost and affordability for cancer care at the 2017 ASCO Annual Meeting in Chicago, IL.

Shinji Atagi, MD of National Hospital Organization Kinki-Chuo Chest Medical Center gives an overview of a randomized trial done by the Japan Clinical Oncology Group on radiotherapy for elderly NSCLC patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8532: Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. discusses what’s next for entrectinib and his hopes to launch the drug globally in the next couple of years. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. gives an overview of his clinical trial, STARTRK-2 and the use of entrectinib, an investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors, at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains the impact of Entrectinib and the STARTRK-2 trial on clinical practice and future clinical trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains genomic testing in finding patients for the clinical trial, STARTRK-2. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. STARTRK-2: A Phase II Study on Use of Entrectinib in NTRK1/2/3, ROS1, or ALK Gene Fusions

David Michael Hyman, MD of Memorial Sloan-Kettering talks of his hopes for LOXO-101 in future clinical practice and clinical trials at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers

David Michael Hyman, MD of Memorial Sloan-Kettering gives an overview his presentation, which focuses on the efficacy of larotrectinib (LOXO-101) in adult and pediatric TRK fusion cancers at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David Michael Hyman, MD of Memorial Sloan-Kettering explains common questions physicians ask him concerning his study on the efficacy of larotrectinib (LOXO-101). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers

William P. Harris, MD of Seattle Cancer Care Alliance gives an overview of some of the promising data coming out of ASCO 2017 in Chicago, IL. He discusses several trials for treatment of advanced intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC)

William P. Harris, MD of Seattle Cancer Care Alliance discusses the treatment trends for upper gastrointestinal cancers, which include targeted therapy and immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

William P. Harris, MD of Seattle Cancer Care Alliance explains some of the common questions asked regarding the phase II trial on pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

William P. Harris, MD of Seattle Cancer Care Alliance discusses metastatic pancreatic cancer for the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

Julie R. Gralow, MD of Seattle Cancer Care Alliance gives an overview of her presentation, SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy

Julie R. Gralow, MD of Seattle Cancer Care Alliance explains the impact of the trial on clinical practice, arguing that the data now shows the important role PARP inhibitors have in metastatic breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy